Skip NavigationSkip to Content

Immunologic and Hematopoietic Effects of Cd40 Stimulation After Syngeneic Bone Marrow Transplantation in Mice

  1. Author:
    Funakoshi, S.
    Taub, D. D.
    Anver, M. R.
    Raziuddin, A.
    Asai, O.
    Reddy, V.
    Rager, H.
    Fanslow, W. C.
    Longo, D. L.
    Murphy, W. J.
  2. Author Address

    Murphy WJ NCI IRSP SAIC FREDERICK FCRDC CLIN SCI PROGRAM BLDG 567 ROOM 141 FREDERICK, MD 21702 USA NCI IRSP SAIC FREDERICK FCRDC CLIN SCI PROGRAM FREDERICK, MD 21702 USA NCI LAB ANIM SCI PROGRAMS SCI APPLICAT INT CORP FCRDC FREDERICK, MD 21702 USA IMMUNEX CORP SEATTLE, WA 98101 USA NCI LAB LEUKOCYTE BIOL BIOL RESPONSE MODIFIERS PROGRAM DIV CANC TREATEMENT FREDERICK, MD 21702 USA
    1. Year: 1997
  1. Journal: Journal of Clinical Investigation
    1. 99
    2. 3
    3. Pages: 484-491
  2. Type of Article: Article
  1. Abstract:

    CD40 is a molecule present on multiple cell types including B lymphocyte lineage cells. CD40 has been shown to play an important role in B cell differentiation and activation in vitro, although little is known concerning the effects of CD40 stimulation in vivo. We therefore examined the effects of CD40 stimulation in mice using a syngeneic bone marrow transplantation (BMT) model in an effort to augment B cell recovery after high dose therapy with hematopoietic reconstitution. After the BMT, mice were treated with or without 2-6 mu g of a soluble recombinant murine CD40 ligand (srmCD40L) given intraperitoneally twice a week. A significant increase in B cell progenitors (B220(+)/ surface IgM(-)) was observed in the bone marrow of mice receiving the srmCD40L. The treated recipients also demonstrated improved B-cell function with increases in total serum immunoglobulin and increased splenic mitogen responsiveness to LPS being noted. Additionally, srmCD40L treatment promoted secondary lymphoid organ repopulation, accelerating germinal center formation in the lymph nodes. Total B cell numbers in the periphery were not significantly affected even with continuous srmCD40L administration. Lymphocytes obtained from mice treated with the ligand also had increases in T cell mitogen and anti-CDS mAb responsiveness and acquired the capability to produce IL-4. Surprisingly, treatment with srmCD40L also produced hematopoietic effects in mice, resulting in an increase of BM and splenic hematopoietic progenitor cells in the mice after BMT. Treatment with srmCD40L significantly increased granulocyte and platelet recovery in the peripheral blood. Incubation of BMC with srmCD40L in vitro also resulted in increased progenitor proliferation, demonstrating that the hematopoietic effects of the ligand may be direct. Thus, stimulation of CD40 by its ligand may be beneficial in accelerating both immune and hematopoietic recovery in the setting of bone marrow transplantation. [References: 33]

    See More

External Sources

  1. No sources found.

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel